Lung metastasis is a major cause of mortality in patients with osteosarcoma (OS). A better understanding of the molecular mechanism of OS lung metastasis may facilitate development of new therapeutic strategies to prevent the metastasis. We have established high-and low-metastatic sublines (LM8-H and LM8-L, respectively) from Dunn OS cell line LM8 by using in vivo image-guided screening. Among the genes whose expression was significantly increased in LM8-H compared to LM8-L, the transcription factor lymphoid enhancer-binding factor 1 (LEF1) was identified as a factor that promotes LM8-H cell extravasation into the lungs. To identify downstream effectors of LEF1 that are involved in OS lung metastasis, 13 genes were selected based on LM8 microarray data and genomewide meta-analysis of a public database for OS patients. Among them, the cytoglobin (Cygb) gene was identified as a key effector in promoting OS extravasation into the lungs. CYGB overexpression increased the extravasation ability of LM8-L cells, whereas knocking out the Cygb gene in LM8-H cells reduced this ability. Our results showed a novel LEF1-CYGB axis in OS lung metastasis and may provide a new way of developing therapeutic strategies to prevent OS lung metastasis.
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| INTRODUCTION
Osteosarcoma (OS) is the most common malignant bone tumor in both children and adults.
1,2 Lung metastasis is a major cause of poor prognosis in OS patients. Although the 5-year survival rate of patients with localized disease is approximately 70%, 3, 4 that of patients with lung metastasis is less than 40%. 4 Because no effective treatment is currently available to improve outcomes, the development of new therapeutic strategies based on the molecular mechanisms of OS lung metastasis is urgently required.
Metastasis is a multistep processes involving epithelial-mesenchymal transition (EMT), invasion, intravasation, circulation, extravasation, seeding, and outgrowth in secondary organs. 5, 6 Because many genes participate in each step, identification of a gene whose function is crucial for a particular step is important for developing a strategy to prevent metastasis. Extravasation occurs when cancer cells migrate to distant organs after entering the circulation. The process involves the adhesion of cancer cells to the endothelium, modulation of the endothelial barrier, and transmigration of cancer cells to reach the underlying tissue. First, adhesion between cancer cells and is implicated in many steps of metastasis, 11 the underlying mechanism whereby LEF1 enhances lung metastasis in OS is still unclear.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Cytoglobin (CYGB) is a member of the globin family of proteins, which include hemoglobin and myoglobin. 13, 14 Cygb was first identified as an inflammatory-and fibrosis-related gene in the liver. 15 In addition, Cygb is also known to function as a tumor suppressor gene [16] [17] [18] and is involved in protective mechanisms against cellular stresses such as cell injury, DNA damage, and hypoxia. 13, 16, [19] [20] [21] [22] CYGB is induced by hypoxia-inducible factor-1α (HIF-1α), nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB), and other inflammation-related transcription factors. 23 Overexpression (OE) of CYGB in lung cancer cells impaired transmigration and anchorage-independent growth under normoxic conditions but promoted these abilities under hypoxic conditions. 19 In the present study, we isolated LM8 sublines with differential abilities to metastasize to the lungs, and molecular genetic analyses of these sublines showed that LEF1-induced CYGB plays a crucial role in the extravasation step during lung metastasis. Our results indicate that a novel LEF1-CYGB axis can potentially serve as a therapeutic target for preventing the lung metastasis of OS.
| MATERIALS AND METHODS

| Cell culture
Murine OS LM8 cell line 24 was gifted by Dr Hideki Yoshikawa (Osaka University, Osaka, Japan). All LM8 sublines were cultured in DMEM supplemented with 5% FBS, penicillin (100 U/mL), and streptomycin (100 μg/mL at 37°C, 5% CO 2 ). Murine vascular endothelia bEnd.3 cells were purchased from the ATCC (Manassas, VA, USA). bEnd.3 cells were cultured in DMEM supplemented with 10% FBS, penicillin (100 U/mL), and streptomycin (100 μg/mL) at 37°C, 5% CO 2 .
| Mice
Male BALB/c nu/nu, SCID, and C3H mice were obtained from
Charles River Laboratory, Japan (Yokohama, Japan). All mice used were 6-8 weeks of age and were housed in the animal facilities at 
| Establishment of LM8-L and LM8-H
The LM8/luc cell line was established by stable transfection with a firefly luciferase gene as described previously. 25 To establish LM8-L cells, which have lost the ability to metastasize to the lungs, LM8/luc cells were intracardially injected into BALB/c nude mice, and LM8/luc cells that metastasized to the bone were isolated with a BL imageguided approach. The isolated cells were cultured and reinjected into nude mice. LM8-L was established after 4 rounds of the imageguided in vivo screening process. LM8-H was selected based on metastatic ability to the lung in C3H mice from LM8-L sublines that were isolated from lung metastases generated after injection of LM8-L into the tibia of SCID mice. 
| Lung metastasis assay
| Histology analysis
Isolated lungs were embedded in optimal cutting temperature (OCT) compound (Sakura Fine Tech, Tokyo, Japan) and stored at −80°C.
Fixed lung cryosections of the lung (10-μm thick) were then stained with HE. | 2747
| Tumor formation ability assay
Seiyaku Corp., Tokyo, Japan). Thirty days after transplantation, tumors were excised and their weights were measured.
| Western blotting
Cell lysates were prepared with RIPA buffer and subjected to western blot analysis using a rabbit anti-LEF1 polyclonal antibody (Ab;
Cell Signaling Technology, Danvers, MA, USA), a rabbit anti-CYGB polyclonal Ab (Thermo Fisher Scientific), and a mouse anti-β-actin monoclonal Ab (Sigma Aldrich, St Louis, MO, USA).
| Cell-proliferation assay
Cell proliferation was evaluated with the water-soluble tetrazolium 
| Extravasation assay
Cells were labeled with 25 μmol/L CellTracker ® Green and i.v. After a 1-hour incubation, each well was washed 3 times with PBS.
Number of LM8 cells attached to the bEnd3 monolayer was observed by fluorescence microscopy (4 fields/well) and quantitatively analyzed using ImageJ software. 26 Each sample was analyzed in triplicate.
| Transmigration assay
bEnd.3 cells ( 10 5 ) were seeded in the top filters with 8-μm-pore Transwell ® plate (Corning, Corning, NY, USA) and grown for 3 days.
LM8 sublines were labeled with 25 μmol/L CellTracker ® Green for 30 minutes. After washing with PBS, the cells (5 × 10 4 ) were seeded on bEnd.3 monolayers. After a 24-hour incubation, the unmigrated cells were wiped off with a cotton swab and, then, the filter was fixed with 4% paraformaldehyde for 20 minutes. The migrated cells on the filter were then observed under a fluorescence microscope (4 fields/filter) and the number of migrated cells was analyzed using
ImageJ software. 26 Results are shown as the average number of cells per field. Each sample was analyzed in triplicate.
| Genomewide meta-analysis
Microarray data sets were downloaded from the public Gene Expression Omnibus (GEO) repository (http://www.ncbi.nlm.nih.gov/gds).
The first data set included low-and high-metastatic clinical OS samples (GSE21257). The second data set included low-and high-metastatic human OS cell lines (GSE49003). The genes commonly upregulated in highly metastatic OS in both data sets were analyzed using GEO2R
(https://www.ncbi.nlm.nih.gov/gds), and genes whose P-values were <.05 were selected. Gene IDs of selected human genes were converted to murine gene IDs using BioMart web software. 
| Reverse transcription-PCR and qPCR
Total RNA was extracted from cell pellets using the RNeasy ® Mini
Kit (Qiagen, Valencia, CA, USA), as recommended by the manufacturer. Total RNA (1 μg) was reverse-transcribed with Oligo(dT)20 Primer (Toyobo Co., Osaka, Japan) and ReverTra Ace (Toyobo Co.).
qPCR and RT-PCR were carried out using Thunderbird ® SYBR qPCR Mix (Toyobo) and EmeraldAmp ® GT PCR Master Mix (Takara, Tokyo, Japan), respectively. The primer sets used for qPCR and RT-PCR are shown in Table S1 .
| Gene KO using the CRISPR-Cas9 system
Two guide RNAs (gRNA1 and gRNA2) used for editing Lef1 and Cygb were constructed using CRISPR design software. 28 The sequences of gRNA1 and gRNA2 used for targeting Lef1 are 5′-TTGTTGTA-CAGGCCTCCGTC-3′ and 5′-GTACGGGTCGCTGTTCATAT-3′, respectively. The sequences of gRNA1 and gRNA2 used for targeting
Cygb are 5′-GAAGGCGGTTCAGGCTACGT-3′ and 5′-TGAAG-TACTGCTTGGCCGAA-3′, respectively. The Lef1 and Cygb gRNAs were inserted into a unique BbsI site of the pX330 plasmid (42230;
Addgene, Cambridge, MA, USA). We used a fluorescence indicator system using the pCAG/EGxxFP plasmid 29 provided by Dr Ikawa (Osaka University, Osaka, Japan) to select cells whose genomes were correctly edited using the CRISPR-Cas9 system. GFP-positive colonies were selected, and 2 independent LM8-H/Lef1-KO and LM8-H/ Cygb-KO clones each were established from the gRNA1-and gRNA2-mediated KO cells.
| Vector construction
The coding sequence of Cygb (NM_030206) was amplified using the KOD ® FX Kit (Toyobo) with the following primer set: forward, 5′- 
| Establishment of an LM8 cell line with stable CYGB overexpression
To establish stable cell lines overexpressing Cygb, the sleeping beauty transposon system was used. [30] [31] [32] The pT2/Cygb or pT2-MCS-SV Neo and pCMV(CAT)T7-SB100 plasmids (34879; Addgene)
were cotransfected into LM8-L cells using an electroporator (Nepa Gene, Chiba, Japan) according to the manufacturer's instructions.
After 48 hours, the culture medium was changed to selection medium containing 1 μg/mL G418 (Roche Life Sciences). The cells were further cultured in selection medium for 14 days, and single colonies were isolated to establish CYGB-overexpressing LM8-L (CYGB-OE) cells.
| Statistical analysis
Data are presented as the mean ± SE and were statistically analyzed with a 2-sided Student's t test. P-values <.05 were considered statistically significant.
| RESULTS
| Establishment of murine OS sublines with differential lung-metastatic abilities
The LM8/luc cell line was previously established 25 These results are consistent with the previous reports 33, 34 and suggest that the larger metastatic foci observed with LM8-H cells were not as a result of its higher degree of outgrowth in the lungs.
| Lymphoid enhancer-binding factor 1 regulated
OS lung metastasis
To identify genes responsible for their differential lung-metastatic abilities of LM8-L and LM8-H cells, their gene-expression profiles
F I G U R E 1 Lm8 cells with different lung-metastatic potential. A, Microphotographs of the high-metastatic (LM8-H) and low-metastatic (LM8-L) cells. B, Lung-metastatic abilities of LM8-L and LM8-H cells. Representative in vivo bioluminescence (BL) images on day 12
(left) and quantitative analysis (right) are shown. BL signals from the lungs were normalized to those on day 0. n = 5, *P < .05. C, Representative HE-stained images of lung tissues at 14 days after injection of the indicated LM8 sublines. D, Subcutaneous tumor formation. LM8 sublines were injected s.c. into C3H mice. Tumors were excised on day 30 (bottom photos). Their weights were measured, and average values are shown. n = 6. *P < .05
were obtained through DNA microarray analysis (Figure 2A ). Gene setenrichment analysis showed that genes associated with LEF1 and several pathways such as AKT and MAPK were enriched in LM8-H cells ( Figure 2B ; Table S3 ). Among them, LEF1-related genes were prominent and highly expressed in LM8-H. Differential LEF1 protein-expression levels in these LM8 sublines were confirmed by western blotting ( Figure 2C ). To examine the significance of LEF1 expression in lungmetastatic ability of LM8-H cells, Lef1 KO cell lines were generated using the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) system, and 2 independent Lef1 KO clones (LM8-H/Lef1-KO1 and LM8-H/Lef1-KO2) were established using different gRNA ( Figure 2D ). When the Lef1 KO clones were i.v. injected into C3H mice, it was found that KO of Lef1 significantly suppressed the lung metastasis of LM8-H cells ( Figure 2E ,F).
| Lymphoid enhancer-binding factor 1 regulated the extravasation step of LM8 sublines
Considering that the results described thus far were obtained using 
| Identification of CYGB as a downstream effector of LEF1
Lymphoid enhancer-binding factor 1 is a well-known transcriptional factor that mediates nuclear responses to Wnt signaling. 11 To identify genes that are regulated by LEF1 and are responsible for the differential extravasation abilities among the LM8 sublines, prometastatic genes downstream of Lef1 were first selected by genomewide meta-analysis and DNA microarray data for the LM8 sublines ( Figure 4A ). By carrying out genomewide meta-analysis with public data sets for human OS cells, 1912 genes were selected as upregulated genes detected in patients with highly metastatic OS. From the DNA microarray data for the LM8-L, LM8-H, and LM8-H/Lef1-KO sublines, 737 genes were selected as upregulated genes in correlation with the metastatic phenotype of the LM8 sublines. The genes selected by the genomewide meta-analysis and the DNA microarray data were compared and 21 overlapping genes were extracted.
Then, 13 out of 21 genes were selected based on their correlation with patient prognosis using the PROGgene database 35 (Table S4 ; Figure S4 ). Expression levels of the 13 candidate genes were analyzed by RT-PCR to examine their correlations with the metastatic phenotype of the LM8 sublines ( Figure S5 ). Among them, the expression levels of Cygb and Ddx58 were well correlated with the metastatic phenotype of the LM8 sublines: their expression levels were high in LM8-H cells and low in LM8-L and LM8-H/lef1KO cells.
Their expression levels were confirmed by qualitative PCR (qPCR) ( Figure 4B ; Figure S6) . Protein-expression level of CYGB was sufficiently correlated with the metastatic phenotype of LM8 sublines: CYGB was highly expressed in LM8-H cells but not in LM8-L and LM8-H/lef1KO cells ( Figure 4C ). For subsequent studies, we analyzed Cygb because the function of Cygb in metastasis has not yet been described, whereas Ddx58 has been reported to promote lung metastasis in several types of cancer. 
| DISCUSSION
In the present study, we identified CYGB as an important regulator of OS extravasation and highlighted the importance of the LEF1-CYGB regulatory axis in OS metastasis to the lungs. To our To explore the possibility that LEF1 directly regulates the expression of CYGB, genome analysis of transcription factor binding sites was carried out using several databases [38] [39] [40] [41] [42] and showed that Cygb has potential LEF1 binding sites in the promoter region ( Figure S7 ).
LEF1 may directly regulate Cygb expression. As CYGB is known to be induced by HIF-1α, NF-κB, and other inflammation-related transcription factors, 23 the interaction of LEF1 with these transcription factors may be important for regulating Cygb expression. Among the 737 genes that were differentially expressed between LM8-L and LM8-H cells, 21 genes were selected as candidate genes responsible for lung metastasis of LM8-H by genomewide meta-analysis, using public data sets from patients with high-and low-metastatic OS.
Expression of 13 out of 21 genes correlated well with cancer prognosis in patients with OS ( Figure S4 ). The gene products of the 13
selected genes function as cell receptors/transporters, cytokines, GTPase-activating proteins and in cell movement (Table S3) We conducted 2 experiments to elucidate the molecular mechanism by which CYGB functions directly in promoting extravasation based on the proposed functions for CYGB. First, as CYGB has been suggested to act as an NO dioxygenase 43 and as NO prevents endothelial activation by inhibiting the expression of adhesion molecules such as vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1), 44, 45 we investigated whether CYGB reduces NO levels in the lung blood vessels, in turn, reducing the expression of adhesion molecules.
We found only slight differences in the total NO species levels and little influence of inhibitors of NO species among the LM8 sublines ( Figure S9 ). Although NO reduction by CYGB may contribute to metastasis, the subtle differences in NO levels among the LM8 sublines cannot explain the significant differences in lung-metastatic potential found among them, suggesting that NO is not a major player in CYGB-mediated extravasation.
Second, as arachidonic acid (AA) increases the migratory activity of cancer cells through activation of RhoA and RhoC, 46 has not yet been identified contributes to promotion of the extravasation.
As we used an i.v. injection model to examine the lung-metastatic abilities of the LM8 sublines, our evaluation was limited to the postcirculation steps of metastasis. To explore the differences between LM8-H and LM8-L cells in precirculation steps, we analyzed the EMT and invasion steps. Although the morphologies of LM8-H and LM8-L cells differ, the expression levels of EMT-related genes (based on microarray data) and the migration and invasion abilities (assessed by wound-healing and invasion assays, respectively) were not significantly different between either cell line (Table S4 ; Fig- ure S11). These findings suggest that their metastatic abilities may not be so very different before the intravasation steps. Because in vitro analyses using cell-adhesion and transmigration assays can also assess their intravasation capacities, the results suggest that LM8-L also has low intravasation ability. Therefore, LM8-L cells may further reduce the frequency of metastasis from the primary tumor site to the lungs when assessed in a model of the total metastasis process.
Further studies elucidating the entire LEF1-CYGB axis should contribute to the development of new therapeutic approaches for preventing OS metastasis to the lungs.
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